Principal Investigator
Frances Valdes
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20231161
Clinical Trial Summary
A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Breast Cancer
Contact Information
Phone Number
305-243-2647